secwatch.observer — SEC 8-K summary
======================================

Issuer:     MapLight Therapeutics, Inc. (MPLT)
CIK:        0001770069
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008267
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MapLight reports $450M cash; Phase 2 ZEPHYR & IRIS topline results now expected Q3 2026
--------------------------------------------------------------------------------

- Preliminary cash and equivalents ~$450M as of Dec 31, 2025.
- Phase 2 ZEPHYR trial for schizophrenia topline results expected Q3 2026; enrollment ahead of schedule.
- Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results also Q3 2026.
- ZEPHYR is a 300-patient randomized double-blind placebo-controlled trial for acute psychosis.
- IRIS trial randomized ~160 adult and adolescent participants with autism spectrum disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526008267/0001193125-26-008267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526008267/mplt-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer